NEOBLADE logo

NEOBLADE

Phase II randomised placebo controlled Neoadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive bladder cancer

NEOBLADE

Phase II randomised placebo controlled Neoadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive bladder cancer
Funding Boehringer Ingelheim
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status In Follow-up
Start Date 15-Aug-2014

Usually, patients with muscle-invasive bladder cancer will receive treatment in two parts. The first part for patients consists of treatment with two different drugs combined (Gemcitabine and Cisplatin) and is known as neo-adjuvant combination chemotherapy.
We are investigating a new combination of drugs given during part one of treatment for patients who have muscle-invasive bladder cancer, to find out if it is a better treatment. This new combination involves adding the new chemotherapy drug Nintedanib to the usual combination of Gemcitabine and Cisplatin.